MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer
Hannah Williams, Dana M. Omer, H Thompson, Sabrina T. Lin, Floris S. Verheij, João Miranda, Jonathan B. Yuval, James Buckley, Michael R. Marco, Li‐Xuan Qin, David Dombroski, R P Kedar, Aytekin Oto, Elena Korngold, Joseph C. Veniero, Sunil Gandhi, Arun Krishnaraj, Minal Jagtiani Sangwaiya, Kirk Ohanian, Dan Vu, Thomas A. Hope, Sonia Lee, Ashish P. Wasnik, Nikhil Madhuripan, Marc J. Gollub, Julio García‐Aguilar, Sujata Patil, Jin K. Kim, Meghan Lee, Richard F. Dunne, Jorge Marcet, Peter A. Cataldo, Blasé N. Polite, Daniel O. Herzig, David Liska, Samuel Oommen, Charles M. Friel, Charles A. Ternent, Andrew L. Coveler, Steven R. Hunt, Anita Gregory, Madhulika G. Varma, Brian L. Bello, Joseph C. Carmichael, John C. Krauss, Ana Gleisner, Philip B. Paty, Martin R. Weiser, Garrett M. Nash, Emmanouil P. Pappou, José G. Guillem, Larissa K. Temple, Iris H. Wei, Maria Widmar, Neil H. Segal, Andrea Cercek, Rona Yaeger, J. Joshua Smith, Karyn A. Goodman, Abraham J. Wu, Leonard B. Saltz
Abstract
Restaging MRI can stratify patients treated with total neoadjuvant therapy into clinical response categories predictive of organ preservation, local regrowth, and survival.